Swiss drugs firm funds London-based self-expression platform.
The corporate venturing unit of Switzerland-based drugs company Debiopharm Group has backed Urturn, a UK-based social platform for self-expression.
The company has raised $13.4m in Series A funding. Venture capital firm Balderton Capital led the round with a $10.7m investment with Debiopharm investing the remaining $2.7m.
Urturn provides its users with templates to customise photos, pull in music and video clips, and then share them on Urturn itself, as well as Facebook and Twitter.
